Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepotastine besilate in pediatric perennial allergic rhinitis
NCT01861522Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Apr 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing TAU-284 with Placebo (2 arms). Primary endpoint: Change From Baseline in Total Score for the Three Major Nasal Symptoms (Sneezing, Rhinorrhea, and Nasal Congestion) at 2 weeks. Started Apr 2013; status: completed.
02
Drugs
bepotastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01861522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861522.